Intuitive Surgical, Inc. (LON:0R29)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 139.49B |
| Revenue (ttm) | 6.75B |
| Net Income (ttm) | 1.92B |
| Shares Out | n/a |
| EPS (ttm) | 5.29 |
| PE Ratio | 72.78 |
| Forward PE | 65.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 349 |
| Average Volume | 2,863 |
| Open | 529.00 |
| Previous Close | 523.81 |
| Day's Range | 525.96 - 539.38 |
| 52-Week Range | 406.50 - 616.00 |
| Beta | 1.68 |
| RSI | 36.88 |
| Earnings Date | Jul 15, 2025 |
About Intuitive Surgical
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling,... [Read more]
Financial Performance
In 2024, Intuitive Surgical's revenue was $8.35 billion, an increase of 17.24% compared to the previous year's $7.12 billion. Earnings were $2.32 billion, an increase of 29.18%.
Financial numbers in USD Financial StatementsNews
US stocks threatens to close at record levels but closes just off record levels
The broader stock indices threatened to close at record levels with the S&P index getting within one point of a record high level. The comes in at 6147.43. The high price today reached 6146.52. The NA...
Major US stocks close mixed. Dow is lower. S&P near unchanged. NASDAQ marginally higher
The major US stock indices closed the day with mixed results following the FOMC decision to keep rates unchanged, as widely expected. The Dow Jones Industrial Average slipped modestly, while the S&P 5...
Here's How Much You Would Have Made Owning Intuitive Surgical Stock In The Last 20 Years
Intuitive Surgical (NASDAQ: ISRG) has outperformed the market over the past 20 years by 17.21% on an annualized basis producing an average annual return of 25.49%. Currently, Intuitive Surgical has a...
Intuitive Surgical: The Market Might Exaggerate The Impact Of Remanufacturing
Intuitive Surgical Stock: Why This Correction Is Healthy And What Lies Ahead
Intuitive Surgical (NASDAQ: ISRG) is currently in Phase 17 of its 18-Phase Adhishthana Cycle. While the recent correction may be causing concern among investors, from the perspective of Adhishthana P...
Intuitive Surgical Stock: Why This Correction Is Healthy And What Lies Ahead
Intuitive Surgical ISRG is currently in Phase 17 of its 18-Phase Adhishthana Cycle. While the recent correction may be causing concern among investors, from the perspective of Adhishthana Principles, ...
Intuitive Surgical analyst raises eyebrows with new stock price target
This is what could happen next to Intuitive Surgical shares.
Why Intuitive Surgical Stock Plunged Today
One former Intuitive Surgical fan thinks it's time to sell the stock.
Intuitive Surgical drops as Deutsche Bank downgrades to sell
Intuitive Surgical stock dubbed a ‘premier, high-growth' name despite first sell rating
Intuitive Surgical Inc. (NASDAQ: ISRG) is deep in the red this morning after Deutsche Bank issued a bearish note on the biotechnology giant based out of Sunnyvale, California.
This Tesla Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Intuitive Surgical Stock Falls. The MedTech Company Gets Its First Sell Rating.
Deutsche Bank is the first group on Wall Street to issue a Sell rating on shares of Intuitive Surgical.
Cramer's Stop Trading: Intuitive Surgical
CNBC's Jim Cramer explains why he is keeping an eye on shares of Intuitive Surgical.
Cramers Stop Trading: Intuitive Surgical
CNBCs Jim Cramer explains why he is keeping an eye on shares of Intuitive Surgical.
Trade Tracker: Stephanie Link sells Nextera and buys more Intuitive Surgical
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
Trade Tracker: Stephanie Link sells Nextera and buys more Intuitive Surgical
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
AVGO Beat and Raise? Plus, Demmert's Stock Picks: ISRG, BYDDY
James Demmert drops by the NYSE set with a couple of stocks to watch: Intuitive Surgical (ISRG) and BYD (BYDDY). He says both are plays that avoid a potential U.S. slowdown.
What the Options Market Tells Us About Intuitive Surgical
Deep-pocketed investors have adopted a bullish approach towards Intuitive Surgical (NASDAQ: ISRG), and it's something market players shouldn't ignore. Our tracking of public options records at Benzin...
How pet medicine stocks could cushion your healthcare investments from Trump changes
Moderna shares are seeing a boost on Monday after the US Food and Drug Administration (FDA) gave the pharmaceutical giant limited approval for its lower-dose COVID-19 vaccine. Morgan Stanley Investmen...
Intuitive Surgical: More Than Robots - Why Its AI-Powered Platform Deserves A Premium
Understanding how implied volatility works for options and how to capitalize on it
Mike Khouw looks at a trade on Intuitive Surgical.
$100 Invested In Intuitive Surgical 5 Years Ago Would Be Worth This Much Today
Intuitive Surgical (NASDAQ: ISRG) has outperformed the market over the past 5 years by 9.52% on an annualized basis producing an average annual return of 23.37%. Currently, Intuitive Surgical has a m...
P/E Ratio Insights for Intuitive Surgical
In the current session, the stock is trading at $555.50, after a 0.56% spike. Over the past month, Intuitive Surgical Inc. (NASDAQ: ISRG) stock increased by 7.71% , and in the past year, by 38.53% . ...
Intuitive Surgical: Moat, Resilience But High Market Expectations
Intuitive Surgical remains a dominant leader in robotic surgery with strong recurring revenues, high switching costs, and robust financial health. Business fundamentals are excellent, with resilient p...